Market Overview:
The global myocardial ischemia treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth can be attributed to the increasing incidence of myocardial ischemia, rising geriatric population, and technological advancements in the field of myocardial ischemia treatment. Based on type, the global myocardial ischemia treatment market can be segmented into medications, surgery, and others. The medications segment dominated the global market in 2017 and is projected to maintain its dominance during the forecast period. This can be attributed to factors such as increasing prevalence of lifestyle diseases and growing awareness about early diagnosis and treatment options for heart diseases among patients worldwide. Based on application, the global myocardial ischemia treatment market can be divided into hospitals, clinics, diagnostic centers, and others segments. The hospitals segment accounted for a major share of the overall market in 2017 owing to rising number of hospital admissions for cardiac procedures across regions worldwide.
Product Definition:
Myocardial ischemia treatment is the process of restoring blood flow to the heart. This can be done through medications, procedures, or surgery. The importance of myocardial ischemia treatment is that it can prevent damage to the heart muscle and improve patient outcomes.
Medications:
Medications, it's usage and growth factor in Myocardial Ischemia Treatment market is expected to witness lucrative growth over the forecast period owing to increasing prevalence of cardiovascular diseases globally. According to the American Heart Association, more than 92 million people in America are living with some form of CVD and this number is expected to reach nearly 111 million by 2030.
Surgery:
The global Surgery and it's usage in Myocardial Ischemia Treatment market is expected to witness significant growth over the forecast period. The key drivers of this market are increasing prevalence of Coronary Artery Disease (CAD) and Percutaneous Coronary Intervention (PCI) procedures along with growing demand for minimally invasive surgeries.
Application Insights:
Based on application, the global myocardial ischemia treatment market is segmented into hospitals, clinics and diagnostic centers, and others. Hospitals held the largest share in 2017 owing to factors such as a large patient base that requires heart surgeries along with increasing awareness about cardiac diseases among other patients.
The clinics and diagnostic centers are anticipated to be the fastest-growing segment over the forecast period due to an increase in demand for noninvasive procedures along with advancements in technology. For instance, CardioMEMS by Medtronic PLC uses ultrasound technology for real-time mapping of blood flow through arteries during treatments. This allows doctors to plan precise amounts of medication without causing damage or discomfort to surrounding tissue. Such technological advancements are expected drive growth over the coming years.
Regional Analysis:
North America dominated the global myocardial ischemia treatment market in 2017. This can be attributed to favorable reimbursement policies, high healthcare expenditure, and increasing awareness about MICS procedures. Moreover, the presence of key players such as Johnson & Johnson Services Inc.; Merck Group; and Pfizer Inc., has led to increased penetration of technologically advanced products for cardiac care.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to factors such as improving healthcare infrastructure with an increase in government initiatives for raising public awareness regarding cardiovascular diseases (CVDs), growing geriatric population prone to CVDs, and economic development leading to improved access of patients suffering from CVDs/ischemic heart disease (IHD) conditions with quality medical treatment at lower costs compared with developed regions. In addition, rising disposable income levels are anticipated favorably impact regional growth over the forecast period.
Growth Factors:
- Increasing incidence of myocardial ischemia
- Rising awareness about myocardial ischemia and its treatment options
- Growing demand for minimally invasive procedures for myocardial ischemia treatment
- Technological advancements in the field of myocardial ischemia treatment
- increasing prevalence of cardiovascular diseases
Scope Of The Report
Report Attributes
Report Details
Report Title
Myocardial Ischemia Treatment Market Research Report
By Type
Medications, Surgery, Others
By Application
Hospitals, Clinics, Diagnostic Centers, Others
By Companies
Pfizer, Novartis, AstraZeneca, Boston Scientific, Johnson & Johnson, Boehringer Ingelheim, Daiichi Sankyo, Merck, Edwards Lifesciences, Bayer, Gene BiOthersapeutics, ViroMed
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
120
Number of Tables & Figures
84
Customization Available
Yes, the report can be customized as per your need.
Global Myocardial Ischemia Treatment Market Report Segments:
The global Myocardial Ischemia Treatment market is segmented on the basis of:
Types
Medications, Surgery, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Diagnostic Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- AstraZeneca
- Boston Scientific
- Johnson & Johnson
- Boehringer Ingelheim
- Daiichi Sankyo
- Merck
- Edwards Lifesciences
- Bayer
- Gene BiOthersapeutics
- ViroMed
Highlights of The Myocardial Ischemia Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medications
- Surgery
- Others
- By Application:
- Hospitals
- Clinics
- Diagnostic Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myocardial Ischemia Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myocardial ischemia treatment is a medical procedure used to improve the blood flow to the heart. This can help to prevent or reduce damage to the heart muscle, which can lead to death.
Some of the major companies in the myocardial ischemia treatment market are Pfizer, Novartis, AstraZeneca, Boston Scientific, Johnson & Johnson, Boehringer Ingelheim, Daiichi Sankyo, Merck, Edwards Lifesciences, Bayer, Gene BiOthersapeutics, ViroMed.
The myocardial ischemia treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myocardial Ischemia Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myocardial Ischemia Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myocardial Ischemia Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myocardial Ischemia Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myocardial Ischemia Treatment Market Size & Forecast, 2020-2028
4.5.1 Myocardial Ischemia Treatment Market Size and Y-o-Y Growth
4.5.2 Myocardial Ischemia Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Medications
5.2.2 Surgery
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Diagnostic Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myocardial Ischemia Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myocardial Ischemia Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Medications
9.6.2 Surgery
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Diagnostic Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Medications
10.6.2 Surgery
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Diagnostic Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Medications
11.6.2 Surgery
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Diagnostic Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Medications
12.6.2 Surgery
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Diagnostic Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Medications
13.6.2 Surgery
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Diagnostic Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myocardial Ischemia Treatment Market: Competitive Dashboard
14.2 Global Myocardial Ischemia Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 AstraZeneca
14.3.4 Boston Scientific
14.3.5 Johnson & Johnson
14.3.6 Boehringer Ingelheim
14.3.7 Daiichi Sankyo
14.3.8 Merck
14.3.9 Edwards Lifesciences
14.3.10 Bayer
14.3.11 Gene BiOthersapeutics
14.3.12 ViroMed
